<?xml version="1.0" encoding="UTF-8"?>
<p>All patients received lopinavir/ritonavir (protease inhibitors) and interferon alfa (an antiviral agent) by inhalation; this combination was previously used to treat patients with MERS.
 <xref rid="mja250577-bib-0020" ref-type="ref">20</xref> Five patients also received umifenovir, which blocks viral endocytosis and replication of a large panel of viruses; it is licensed in Russia and China for treating and preventing influenza.
 <xref rid="mja250577-bib-0021" ref-type="ref">21</xref> Moxifloxacin monotherapy was used as prophylactic antimicrobial treatment in 14 patients for a median 6.5 days (IQR, 3.5â€“7.0 days).
</p>
